$RXST
RxSight, Inc. Stock $rxst

$rxst Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000095017024053566 Filed on May 06, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$34.89M	$29.51M	$17.49M
YoY Change	67.65%	68.75%	95.58%
Cost Of Revenue	$10.64M	$8.827M	$7.123M
YoY Change	20.94%	23.92%	37.48%
Gross Profit	$24.25M	$20.69M	$10.37M
YoY Change	101.83%	99.55%	175.62%
Gross Profit Margin	69.51%	70.09%	59.27%
Selling, General & Admin	$24.29M	$23.32M	$16.26M
YoY Change	33.08%	43.49%	19.35%
% of Gross Profit	100.17%	112.76%	156.81%
Research & Development	$8.291M	$8.031M	$7.208M
YoY Change	12.83%	11.42%	7.28%
% of Gross Profit	34.19%	38.83%	69.54%
Depreciation & Amortization	$820.0K	$1.115M	$955.0K
YoY Change	-20.39%	16.75%	-6.0%
% of Gross Profit	3.38%	5.39%	9.21%
Operating Expenses	$32.58M	$31.36M	$23.46M
YoY Change	27.08%	33.64%	15.36%
Operating Profit	-$8.333M	-$10.67M	-$13.10M
YoY Change	-38.84%	-18.53%	-21.0%
Interest Expense	$6.000K	$6.000K	$1.507M
YoY Change	-97.13%	-99.6%	42.17%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.063M	-$9.091M	-$13.21M
YoY Change	-56.0%	-31.19%	-24.9%
Income Tax	$16.00K	$9.000K	$0.00
% Of Pretax Income
Net Earnings	-$6.079M	-$9.100M	-$13.21M
YoY Change	-55.96%	-31.12%	-24.91%
Net Earnings / Revenue	-17.42%	-30.83%	-75.54%
Basic Earnings Per Share	-$0.16	-$0.25	-$0.42
Diluted Earnings Per Share	-$0.16	-$0.25	-$0.42
COMMON SHARES
Basic Shares Outstanding	37.20M	36.99M	33.78M
Diluted Shares Outstanding	38.46M	36.84M	31.64M

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$233.3M	$125.4M	$153.9M
YoY Change	58.6%	-18.57%	7.02%
Cash & Equivalents	$24.45M	$32.65M	$11.01M
Short-Term Investments	$208.8M	$92.71M	$142.9M
Other Short-Term Assets	$2.773M	$2.955M	$2.992M
YoY Change	31.3%	-1.24%	-6.03%
Inventory	$19.44M	$18.70M	$18.07M
Prepaid Expenses
Receivables	$25.72M	$21.55M	$12.67M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$281.2M	$168.6M	$187.7M
YoY Change	55.85%	-10.18%	16.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.44M	$11.62M	$9.804M
YoY Change	-9.21%	18.49%	-10.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$303.0K	$226.0K	$746.0K
YoY Change	-72.68%	-69.71%	465.15%
Total Long-Term Assets	$24.28M	$14.61M	$14.87M
YoY Change	63.85%	-1.75%	-6.59%
TOTAL ASSETS
Total Short-Term Assets	$281.2M	$168.6M	$187.7M
Total Long-Term Assets	$24.28M	$14.61M	$14.87M
Total Assets	$305.5M	$183.2M	$202.5M
YoY Change	56.46%	-9.56%	14.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.095M	$5.057M	$3.717M
YoY Change	27.47%	36.05%	43.68%
Accrued Expenses	$14.50M	$13.25M	$11.05M
YoY Change	16.07%	19.94%	38.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$26.00K	$24.00K	$114.0K
YoY Change	-66.67%	-78.95%	52.0%
Total Short-Term Liabilities	$19.62M	$18.33M	$14.88M
YoY Change	18.43%	23.21%	39.56%
LONG-TERM LIABILITIES
Long-Term Debt	$121.0K	$120.0K	$40.31M
YoY Change	-99.38%	-99.7%	0.84%
Other Long-Term Liabilities	$10.55M	$788.0K	$2.338M
YoY Change	449.92%	-66.3%	-28.41%
Total Long-Term Liabilities	$10.67M	$908.0K	$42.65M
YoY Change	-50.37%	-97.87%	-1.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.62M	$18.33M	$14.88M
Total Long-Term Liabilities	$10.67M	$908.0K	$42.65M
Total Liabilities	$30.29M	$19.24M	$57.52M
YoY Change	-20.44%	-66.56%	6.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$609.8M	-$603.7M	-$559.2M
YoY Change	6.42%	7.96%	12.55%
Common Stock	$40.00K	$37.00K	$34.00K
YoY Change	14.29%	8.82%	25.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$275.2M	$163.9M	$145.0M
YoY Change
Total Liabilities & Shareholders Equity	$305.5M	$183.2M	$202.5M
YoY Change	56.46%	-9.56%	14.38%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$6.079M	-$9.100M	-$13.21M
YoY Change	-55.96%	-31.12%	-24.91%
Depreciation, Depletion And Amortization	$820.0K	$1.115M	$955.0K
YoY Change	-20.39%	16.75%	-6.0%
Cash From Operating Activities	-$4.027M	-$9.309M	-$17.76M
YoY Change	-46.63%	-47.6%	18.55%
INVESTING ACTIVITIES
Capital Expenditures	$1.523M	$1.967M	$747.0K
YoY Change	-16.46%	163.32%	101.89%
Acquisitions
YoY Change
Other Investing Activities	-$114.1M	$26.24M	-$47.62M
YoY Change	-1935.35%	-155.11%	-412.68%
Cash From Investing Activities	-$115.6M	$24.27M	-$48.37M
YoY Change	-2731.29%	-150.19%	-425.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	111.5M	7.992M	65.31M
YoY Change	12411.0%	-87.76%	-66737.76%
NET CHANGE
Cash From Operating Activities	-4.027M	-9.309M	-17.76M
Cash From Investing Activities	-115.6M	24.27M	-48.37M
Cash From Financing Activities	111.5M	7.992M	65.31M
Net Change In Cash	-8.199M	22.95M	-822.0K
YoY Change	262.79%	-2892.46%	258.95%
FREE CASH FLOW
Cash From Operating Activities	-$4.027M	-$9.309M	-$17.76M
Capital Expenditures	$1.523M	$1.967M	$747.0K
Free Cash Flow	-$5.550M	-$11.28M	-$18.51M
YoY Change	-40.76%	-39.08%	20.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001111485
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20240331#LeaseLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20240331#LeaseLiabilitiesCurrent
CY2024Q1	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20240331#LeaseLiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20240331#LeaseLiabilitiesCurrent
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20240331#LeaseLiabilitiesNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20240331#LeaseLiabilitiesNoncurrent
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20240331#LeaseLiabilitiesNoncurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://rxsight.com/20240331#LeaseLiabilitiesNoncurrent
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-40690
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	RxSIGHT, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3268801
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Columbia
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Aliso Viejo
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92656
CY2024Q1	dei	City Area Code CityAreaCode	949
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	521-7830
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	RXST
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37196339
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32645000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9692000
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	92709000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	117490000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21550000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20281000
CY2024Q1	us-gaap	Inventory Net InventoryNet	18700000
CY2023Q4	us-gaap	Inventory Net InventoryNet	17421000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2955000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3523000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	168559000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	168407000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11617000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10841000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2052000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2444000
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	711000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	711000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	226000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	147000
CY2024Q1	us-gaap	Assets Assets	183165000
CY2023Q4	us-gaap	Assets Assets	182550000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5057000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3863000
CY2024Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11657000
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	15239000
CY2024Q1	rxst	Lease Liabilities Current LeaseLiabilitiesCurrent	1614000
CY2023Q4	rxst	Lease Liabilities Current LeaseLiabilitiesCurrent	1801000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18328000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20903000
CY2024Q1	rxst	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	908000
CY2023Q4	rxst	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	1211000
CY2024Q1	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	0
CY2023Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	74000
CY2024Q1	us-gaap	Liabilities Liabilities	19236000
CY2023Q4	us-gaap	Liabilities Liabilities	22188000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37161753
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37161753
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36139513
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36139513
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	37000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	36000
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	767685000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	754971000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-53000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-603740000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-594640000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	163929000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	160362000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	183165000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	182550000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29512000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17489000
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8827000
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7123000
CY2024Q1	us-gaap	Gross Profit GrossProfit	20685000
CY2023Q1	us-gaap	Gross Profit GrossProfit	10366000
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23324000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16255000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8031000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7208000
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	31355000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	23463000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10670000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13097000
CY2024Q1	us-gaap	Interest Expense InterestExpense	6000
CY2023Q1	us-gaap	Interest Expense InterestExpense	1507000
CY2024Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1585000
CY2023Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1392000
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9091000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13212000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9100000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13212000
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-45000
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	84000
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3000
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-48000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	86000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9148000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13126000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36843087
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36843087
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31637097
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31637097
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	160362000
CY2024Q1	rxst	Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount	10153000
CY2024Q1	rxst	Shares Redeemed For Employee Tax With Holdings Amount SharesRedeemedForEmployeeTaxWithHoldingsAmount	-2134000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4696000
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-45000
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-3000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9100000
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	163929000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	89902000
CY2023Q1	rxst	Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount	761000
CY2023Q1	rxst	Shares Redeemed For Employee Tax With Holdings Amount SharesRedeemedForEmployeeTaxWithHoldingsAmount	-337000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3295000
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53600000
CY2023Q1	rxst	Issuance Of Common Stock In At The Market Offerings Net Of Issuance Costs Amount IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount	10914000
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	84000
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	2000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13212000
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	145009000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-9100000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-13212000
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1115000
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	955000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	25000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	44000
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	141000
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1505000
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1257000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4696000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3295000
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	111000
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	10000
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1269000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1712000
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1390000
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3241000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-569000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	460000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1176000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1163000
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3737000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3490000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9309000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17764000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1967000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	747000
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	74000000
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	60000000
CY2024Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	47759000
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	107618000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24274000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48365000
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	54050000
CY2024Q1	rxst	Proceeds From Issuance Of Common Stock In At The Market Offerings ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings	0
CY2023Q1	rxst	Proceeds From Issuance Of Common Stock In At The Market Offerings ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings	11102000
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10153000
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	125400000
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	127200000
CY2024Q1	rxst	Operating Income Loss1 OperatingIncomeLoss1	10700000
CY2023Q1	rxst	Operating Income Loss1 OperatingIncomeLoss1	13100000
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	761000
CY2024Q1	rxst	Payments For Employee Taxes Related To Stock Compensation PaymentsForEmployeeTaxesRelatedToStockCompensation	-2134000
CY2023Q1	rxst	Payments For Employee Taxes Related To Stock Compensation PaymentsForEmployeeTaxesRelatedToStockCompensation	-337000
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27000
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	41000
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	230000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7992000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	65305000
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22954000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-822000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10402000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12595000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33356000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11773000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	548000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	546000
CY2024Q1	rxst	Interest Paid On Financing Leases InterestPaidOnFinancingLeases	5000
CY2023Q1	rxst	Interest Paid On Financing Leases InterestPaidOnFinancingLeases	4000
CY2024Q1	rxst	Interest Paid On Term Loan InterestPaidOnTermLoan	0
CY2023Q1	rxst	Interest Paid On Term Loan InterestPaidOnTermLoan	1344000
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	9000
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2024Q1	rxst	Finance Lease Obligations Incurred FinanceLeaseObligationsIncurred	9000
CY2023Q1	rxst	Finance Lease Obligations Incurred FinanceLeaseObligationsIncurred	0
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	343000
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	259000
CY2024Q1	rxst	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	225000
CY2023Q1	rxst	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	466000
CY2024Q1	rxst	Reclassification Of Deferred Cost ReclassificationOfDeferredCost	0
CY2023Q1	rxst	Reclassification Of Deferred Cost ReclassificationOfDeferredCost	-55000
CY2024Q1	rxst	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2024Q1	us-gaap	Inventory Gross InventoryGross	19285000
CY2023Q4	us-gaap	Inventory Gross InventoryGross	17917000
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	585000
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	496000
CY2024Q1	us-gaap	Inventory Net InventoryNet	18700000
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the condensed consolidated financial statements and disclosures in the accompanying notes as of the date of the accompanying condensed consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. Actual results may differ materially from the estimates used in the preparation of the accompanying condensed consolidated financial statements under different assumptions or conditions.</span></p>
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	36000000
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	10000000
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company’s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money market funds and U.S. treasury bills. A portion of the Company's operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limits; however, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company’s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company’s business and may impact business in the future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to the risks related to global lead times, particularly in Europe and Asia, leading to a supply interruption from the Company's suppliers. In addition, the Company is currently experiencing inflation and longer lead times and limited availability in its supply chain for certain components and has continued exposure to price and supply risk related to anticipated purchases of certain commodities, materials and products used in its business.</span></p>
CY2024Q1	rxst	Accounts Receivable Percentage AccountsReceivablePercentage	0.10
CY2023	rxst	Accounts Receivable Percentage AccountsReceivablePercentage	0.10
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2023Q4	us-gaap	Inventory Net InventoryNet	17421000
CY2024Q1	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	4900000
CY2023Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	4400000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29512000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17489000
CY2023Q4	rxst	Deferred Revenue1 DeferredRevenue1	-1888000
CY2022Q4	rxst	Deferred Revenue1 DeferredRevenue1	-1191000
CY2024Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	963000
CY2023Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	795000
CY2024Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	840000
CY2023Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	598000
CY2024Q1	rxst	Deferred Revenue1 DeferredRevenue1	-2011000
CY2023Q1	rxst	Deferred Revenue1 DeferredRevenue1	-1388000
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9371000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8092000
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5351000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5680000
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	4563000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4145000
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	117506000
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	121965000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over four years as follows, subject to the optionee’s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary and then 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years, or (ii) 1/48th of the total number of shares subject to the option vest and become exercisable each month over four years.
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6777404
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.02
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M3D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	787102
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	55.86
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	941617
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.78
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	56806
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.19
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	9680
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.13
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6556403
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.48
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3615132
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.23
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M9D
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	15900000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8300000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.71
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.651
CY2024Q1	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate	0.042
CY2023Q1	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate	0.041
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2024Q1	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife	P6Y
CY2023Q1	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife	P6Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield	0
CY2024Q1	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue	55.89
CY2023Q1	rxst	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue	14.86
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8787558
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8364218
CY2022Q2	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P34M
CY2022Q2	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2025-03-31
CY2022Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	11410
CY2023Q2	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	5319
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2052000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2444000
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	140000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	156000
CY2024Q1	rxst	Total Lease Assets TotalLeaseAssets	2192000
CY2023Q4	rxst	Total Lease Assets TotalLeaseAssets	2600000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1590000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1764000
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	24000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	37000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	788000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1093000
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	120000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	118000
CY2024Q1	rxst	Total Lease Liabilities TotalLeaseLiabilities	2522000
CY2023Q4	rxst	Total Lease Liabilities TotalLeaseLiabilities	3012000
CY2024Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5000
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1422000
CY2024Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	32000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1054000
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	43000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	90000
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	43000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11000
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	43000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10000
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	36000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2587000
CY2024Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	197000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	209000
CY2024Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	53000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2378000
CY2024Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	144000
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M3D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M8D
CY2024Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M13D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.104
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.104
CY2024Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.144
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.14
CY2024Q1	us-gaap	Legal Fees LegalFees	0
CY2023	us-gaap	Legal Fees LegalFees	0
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000950170-24-053566-index-headers.html	Edgar Link	pending
0000950170-24-053566-index.html	Edgar Link	pending
0000950170-24-053566.txt	Edgar Link	pending
0000950170-24-053566-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rxst-20240331.htm	Edgar Link	pending
rxst-20240331.xsd	Edgar Link	pending
rxst-ex31_1.htm	Edgar Link	pending
rxst-ex31_2.htm	Edgar Link	pending
rxst-ex32_1.htm	Edgar Link	pending
rxst-ex32_2.htm	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
rxst-20240331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RXST
RxSight, Inc. Stock $rxst

2024 Q2 Form 10-Q Financial Statement

#000095017024053566 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RXST RxSight, Inc. Stock $rxst

2024 Q2 Form 10-Q Financial Statement

#000095017024053566 Filed on May 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RXST
RxSight, Inc. Stock $rxst